Sugi Predict

Sugi Predict / Compounds / SCHEMBL506071

SCHEMBL506071

SCHEMBL506071

Cn1cc(B2OC(C)(C)C(C)(C)O2)ccc1=O

nearest known ligand 0.44

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ LPL P06858 12/20 0.44
▸ LIPG Q9Y5X9 12/20 0.44
▸ CA1 P00915 2/20 0.41
▸ CA2 P00918 2/20 0.41
▸ CA9 Q16790 2/20 0.41
▸ CA12 O43570 1/20 0.41
▸ CA3 P07451 1/20 0.41
▸ CA4 P22748 1/20 0.41
▸ CA6 P23280 1/20 0.41
▸ CA5A P35218 1/20 0.41
▸ CA7 P43166 1/20 0.41
▸ CA14 Q9ULX7 1/20 0.41
▸ CA5B Q9Y2D0 1/20 0.41
▸ F11 P03951 2/20 0.37
▸ P4HB P07237 1/20 0.36
▸ FFAR1 O14842 1/20 0.36
▸ IDH1 O75874 1/20 0.36
▸ F2 P00734 1/20 0.35
▸ PRSS1 P07477 1/20 0.35
▸ PRSS2 P07478 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29849103 0.88 LPL (0.42) LPLLIPGCA1CA2CA9
SCHEMBL22325994 0.87 BRD4 (0.37) LPLLIPGCA1CA2CA9
SCHEMBL2383815 0.87 LIPG (0.56) LPLLIPGCA1CA2CA9
SCHEMBL31097871 0.84 LPL (0.32) LPLLIPGCA1CA2CA9
SCHEMBL22339446 0.81 LPL (0.43) LPLLIPGCA1CA2CA9
SCHEMBL28362230 0.79 IDH1 (0.32) IDH1
SCHEMBL16465393 0.79 LIPG (0.47) LPLLIPGCA1CA2CA9
SCHEMBL20641287 0.78 IDH1 (0.33) IDH1
SCHEMBL506778 0.78 LPL (0.46) LPLLIPGCA1CA2CA9
SCHEMBL505914 0.78 LPL (0.41) LPLLIPGCA1CA2CA9

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 819 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-111018858-B Heterocyclic derivative and preparation method and application thereof 复旦大学 2022-11-18 — — CN claimed
CN-111018858-A Heterocyclic derivative and preparation method and application thereof 复旦大学 2020-04-17 — — CN claimed
US-20260146035-A1 FUSED BICYCLIC COMPOUNDS AND THEIR USE AS MER AND AXL INHIBITORS DONG-A ST CO., LTD. (KR) 2026-05-28 — — US disclosed
WO-2026090477-A1 HELICASE INHIBITORS AND USES THEREOF KIMIA THERAPEUTICS, INC. (US) 2026-04-30 — — WO disclosed
US-20260108546-A1 GIP RECEPTOR AGONIST COMPOUNDS LILLY CO ELI (US) 2026-04-23 — — US disclosed
US-20260091048-A1 GIP RECEPTOR AGONIST COMPOUNDS LILLY CO ELI (US) 2026-04-02 — — US disclosed
EP-3768675-B1 NOVEL TRIAZOLONE DERIVATIVES OR SALTS THEREOF AND PHARMACEUTICAL COMPOSITIONS COMPRISING THE SAME YUHAN CORP (KR) 2026-04-01 — — EP disclosed
US-20260085073-A1 PYRAZOLYLCARBOXAMIDE COMPOUNDS AND THEIR USE IN THERAPY HOTSPOT THERAPEUTICS INC (US) 2026-03-26 — — US disclosed
EP-4713095-A1 COMPOUNDS, COMPOSITIONS AND METHODS OF TREATING DISORDERS Chengdu Anticancer Bioscience, Ltd. (CN) 2026-03-25 — — EP disclosed
EP-4192823-B9 DIFLUOROMETHYL-PYRIDIN-2-YL TRIAZOLES SANIONA AS (DK) 2026-03-18 — — EP disclosed
US-12581252-B2 Substituted pyrrolo[3,4-b]pyridines as PI3K-α inhibitors RELAY THERAPEUTICS, INC. (US) 2026-03-17 — — US disclosed
US-20090124612-A1 Fused heterocyclic derivatives and methods of use AMGEN INC. (US) 2009-05-14 — — US disclosed
US-20090124612-A1 Fused heterocyclic derivatives and methods of use AMGEN INC. (US) 2009-05-14 — — US disclosed
US-20090124612-A1 Fused heterocyclic derivatives and methods of use AMGEN INC. (US) 2009-05-14 — — US disclosed
US-20090124609-A1 Fused heterocyclic derivatives and methods of use AMGEN INC. (US) 2009-05-14 — — US disclosed
US-20090124609-A1 Fused heterocyclic derivatives and methods of use AMGEN INC. (US) 2009-05-14 — — US disclosed
WO-2008141119-A2 MODULATORS OF CFTR VERTEX PHARMACEUTICALS INCORPORATED (US) 2008-11-20 — — WO disclosed
WO-2008141119-A2 MODULATORS OF CFTR VERTEX PHARMACEUTICALS INCORPORATED (US) 2008-11-20 — — WO disclosed
WO-2008078091-A1 BICYCLIC HETEROCYCLIC COMPOUNDS AS FGFR INHIBITORS ASTEX THERAPEUTICS LIMITED (GB) 2008-07-03 — — WO disclosed
WO-2008008539-A2 FUSED HETEROCYCLIC DERIVATIVES USEFUL AS INHIBITORS OF THE HEPATOCYTE GROWTH FACTOR RECEPTOR AMGEN INC. (US) 2008-01-17 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090124612-A1 Fused heterocyclic derivatives and methods of use HGF, HGFAC, MET LPL 1103/4885LIPG 558/4885CA1 2847/4885
US-20260091048-A1 GIP RECEPTOR AGONIST COMPOUNDS GIPR, GLP1R, GPR119 LPL 908/4885LIPG 2986/4885CA1 2934/4885
US-20260146035-A1 FUSED BICYCLIC COMPOUNDS AND THEIR USE AS MER AND AXL INHIBITORS AXL, ERBB2, ERBB3 LPL 3855/4885LIPG 3515/4885CA1 1107/4885
US-20260108546-A1 GIP RECEPTOR AGONIST COMPOUNDS GIPR, GLP1R, GCGR LPL 642/4885LIPG 2425/4885CA1 3414/4885
US-20260085073-A1 PYRAZOLYLCARBOXAMIDE COMPOUNDS AND THEIR USE IN THERAPY MALT1, BCL6, BCL3 LPL 2815/4885LIPG 3271/4885CA1 748/4885
US-12581252-B2 Substituted pyrrolo[3,4-b]pyridines as PI3K-α inhibitors RORB, ROR1, RORA LPL 2360/4885LIPG 3692/4885CA1 2126/4885
US-20090124609-A1 Fused heterocyclic derivatives and methods of use HGF, HGFAC, MET LPL 1103/4885LIPG 558/4885CA1 2847/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.